HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 24MG 24 MG
HYDROMORPHONE HYDROCHLORIDE : 24 MG · DIN 02125382 · PURDUE PHARMA
Health Canada status: MARKETED
What is HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 24MG?
HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 24MG 24 MG contains HYDROMORPHONE HYDROCHLORIDE : 24 MG. It is listed in the Health Canada Drug Product Database under DIN 02125382, held by PURDUE PHARMA, supplied as CAPSULE (SUSTAINED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1996. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 24MG used for?
Management of pain in adults severe enough to require daily, continuous, long-term opioid treatment for which alternative options are inadequate. Not for as-needed use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02125382 |
|---|---|
| Brand name | HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 24MG |
| Generic / active ingredient | HYDROMORPHONE HYDROCHLORIDE : 24 MG |
| Manufacturer | PURDUE PHARMA |
| Strength | 24 MG |
| Dosage form | CAPSULE (SUSTAINED-RELEASE) |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA03 HYDROMORPHONE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1996 |
| Original market date | 1996-12-31 00:00:00 |
How is it administered?
Must be swallowed whole or sprinkled on soft food; do not crush/chew. Individualized dosing; opioid-naïve start at 3 mg every 12 hours. Titrate at 48-hour intervals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Keep in a secure location to avoid theft or misuse.
How is it supplied?
Opaque plastic bottles of 50 and 60 capsules.
Contraindications
Hypersensitivity to opioids; gastrointestinal obstruction; acute/severe asthma or respiratory depression; acute alcoholism; convulsive disorders; head injury; MAOI use within 14 days; pregnancy/nursing.
Warnings and precautions
Risk of addiction, abuse, and misuse. Life-threatening respiratory depression. Fatal if swallowed broken, crushed, or chewed. Risk of interaction with benzodiazepines and alcohol.
Is HYDROMORPHONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by STERIMAX INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 24MG
What can be used instead?
Other Canadian products sharing ATC code N02AA03 HYDROMORPHONE. 34 of 85 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-HYDROMORPHONE | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02364115 |
| APO-HYDROMORPHONE | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02364123 |
| APO-HYDROMORPHONE | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02364131 |
| APO-HYDROMORPHONE | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02364158 |
| DILAUDID | 1 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00705438 |
| DILAUDID | 2 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00125083 |
| DILAUDID | 4 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00125121 |
| DILAUDID | 8 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00786543 |
| HYDROMORPH CONTIN | 4.5 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02359502 |
| HYDROMORPH CONTIN | 9 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02359510 |
Who else supplies HYDROMORPHONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROMORPHONE appears in 134 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 24MG
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.